Research ExplorerPublicationsBisphosphonate-related osteonecrosis of the maxilla and sinu...

Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris

Standard

Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris. / Maurer, P; Sandulescu, T; Kriwalsky, M S; Rashad, A; Hollstein, S; Stricker, I; Hölzle, F; Kunkel, M.

In: INT J ORAL MAX SURG, Vol. 40, No. 3, 03.2011, p. 285-91.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Maurer, P, Sandulescu, T, Kriwalsky, MS, Rashad, A, Hollstein, S, Stricker, I, Hölzle, F & Kunkel, M 2011, 'Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris', INT J ORAL MAX SURG, vol. 40, no. 3, pp. 285-91. https://doi.org/10.1016/j.ijom.2010.11.006

APA

Maurer, P., Sandulescu, T., Kriwalsky, M. S., Rashad, A., Hollstein, S., Stricker, I., Hölzle, F., & Kunkel, M. (2011). Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris. INT J ORAL MAX SURG, 40(3), 285-91. https://doi.org/10.1016/j.ijom.2010.11.006

Vancouver

Maurer P, Sandulescu T, Kriwalsky MS, Rashad A, Hollstein S, Stricker I et al. Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris. INT J ORAL MAX SURG. 2011 Mar;40(3):285-91. https://doi.org/10.1016/j.ijom.2010.11.006

Bibtex

@article{c0a2f920e4fa4bd3b29ff501c41b7663,
title = "Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris",
abstract = "Bisphosphonates (BPs) are widely used as bone-stabilizers, but side effects of BP therapy include bisphosphonate-related osteonecrosis of the jaw (BRONJ), which is resistant to therapy. The aim of this study was to evaluate the outcome of maxillary BRONJ involving sinusitis maxillaris. 21 patients presenting with maxillary BRONJ, from 2005 to 2008, were included in the study. In 18 cases BP had been administered for carcinoma and in 3 cases for osteoporosis, with an average exposure time of 47.4 months. 12 patients spontaneously developed BRONJ. The 10 patients diagnosed with stage III BRONJ presented with concomitant sinusitis maxillaris. Despite treatment, there were six recurrences of BRONJ, four of them with additional sinusitis maxillaris. Whether BRONJ occurred spontaneously or after extraction there was no difference in the outcome. Patients with advanced maxillary BRONJ often suffer from sinusitis maxillaris, both of which are frequently resistant to therapy.",
keywords = "Aged, Aged, 80 and over, Amoxicillin-Potassium Clavulanate Combination, Anti-Bacterial Agents, Bone Density Conservation Agents, Carcinoma, Chronic Disease, Debridement, Diphosphonates, Female, Follow-Up Studies, Humans, Imidazoles, Injections, Intravenous, Male, Maxillary Diseases, Maxillary Sinusitis, Middle Aged, Osteonecrosis, Osteoporosis, Osteotomy, Recurrence, Risk Factors, Time Factors, Tomography, X-Ray Computed, Treatment Outcome, Zoledronic Acid, Journal Article",
author = "P Maurer and T Sandulescu and Kriwalsky, {M S} and A Rashad and S Hollstein and I Stricker and F H{\"o}lzle and M Kunkel",
note = "Copyright {\textcopyright} 2010 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.",
year = "2011",
month = mar,
doi = "10.1016/j.ijom.2010.11.006",
language = "English",
volume = "40",
pages = "285--91",
journal = "INT J ORAL MAX SURG",
issn = "0901-5027",
publisher = "Churchill Livingstone",
number = "3",

}

RIS

TY - JOUR

T1 - Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris

AU - Maurer, P

AU - Sandulescu, T

AU - Kriwalsky, M S

AU - Rashad, A

AU - Hollstein, S

AU - Stricker, I

AU - Hölzle, F

AU - Kunkel, M

N1 - Copyright © 2010 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

PY - 2011/3

Y1 - 2011/3

N2 - Bisphosphonates (BPs) are widely used as bone-stabilizers, but side effects of BP therapy include bisphosphonate-related osteonecrosis of the jaw (BRONJ), which is resistant to therapy. The aim of this study was to evaluate the outcome of maxillary BRONJ involving sinusitis maxillaris. 21 patients presenting with maxillary BRONJ, from 2005 to 2008, were included in the study. In 18 cases BP had been administered for carcinoma and in 3 cases for osteoporosis, with an average exposure time of 47.4 months. 12 patients spontaneously developed BRONJ. The 10 patients diagnosed with stage III BRONJ presented with concomitant sinusitis maxillaris. Despite treatment, there were six recurrences of BRONJ, four of them with additional sinusitis maxillaris. Whether BRONJ occurred spontaneously or after extraction there was no difference in the outcome. Patients with advanced maxillary BRONJ often suffer from sinusitis maxillaris, both of which are frequently resistant to therapy.

AB - Bisphosphonates (BPs) are widely used as bone-stabilizers, but side effects of BP therapy include bisphosphonate-related osteonecrosis of the jaw (BRONJ), which is resistant to therapy. The aim of this study was to evaluate the outcome of maxillary BRONJ involving sinusitis maxillaris. 21 patients presenting with maxillary BRONJ, from 2005 to 2008, were included in the study. In 18 cases BP had been administered for carcinoma and in 3 cases for osteoporosis, with an average exposure time of 47.4 months. 12 patients spontaneously developed BRONJ. The 10 patients diagnosed with stage III BRONJ presented with concomitant sinusitis maxillaris. Despite treatment, there were six recurrences of BRONJ, four of them with additional sinusitis maxillaris. Whether BRONJ occurred spontaneously or after extraction there was no difference in the outcome. Patients with advanced maxillary BRONJ often suffer from sinusitis maxillaris, both of which are frequently resistant to therapy.

KW - Aged

KW - Aged, 80 and over

KW - Amoxicillin-Potassium Clavulanate Combination

KW - Anti-Bacterial Agents

KW - Bone Density Conservation Agents

KW - Carcinoma

KW - Chronic Disease

KW - Debridement

KW - Diphosphonates

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Imidazoles

KW - Injections, Intravenous

KW - Male

KW - Maxillary Diseases

KW - Maxillary Sinusitis

KW - Middle Aged

KW - Osteonecrosis

KW - Osteoporosis

KW - Osteotomy

KW - Recurrence

KW - Risk Factors

KW - Time Factors

KW - Tomography, X-Ray Computed

KW - Treatment Outcome

KW - Zoledronic Acid

KW - Journal Article

U2 - 10.1016/j.ijom.2010.11.006

DO - 10.1016/j.ijom.2010.11.006

M3 - SCORING: Journal article

C2 - 21163624

VL - 40

SP - 285

EP - 291

JO - INT J ORAL MAX SURG

JF - INT J ORAL MAX SURG

SN - 0901-5027

IS - 3

ER -